Previous 10 | Next 10 |
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced positiv...
2023-11-01 09:35:34 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma For further details see: GT Biopharma GAAP EPS of -$0.06
IND submission for GTB-3650, 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia, expected in Q4 2023 Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia anticipated in 2024 Cash of approximately $16 million a...
FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...
GT Biopharma Inc. (GTBP) is expected to report $-0.1 for Q3 2023
2023-08-07 10:52:09 ET GT Biopharma press release ( NASDAQ: GTBP ): Q2 GAAP EPS of -$0.05. The Company had cash, cash equivalents and short-term investments of $18.0 million as of June 30, 2023, compared to $16.5 million as of December 31, 2022. For further details s...
C ash of approximately $ 1 8.0 million as of June 30 , 202 3 , provide s ample runway to fund operations into Q 3 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and initiate clinical trial ...
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that Dr...
2023-05-15 17:33:22 ET GT Biopharma press release ( NASDAQ: GTBP ): Q1 GAAP EPS of -$0.01 beats by $0.15 . The Company had cash, cash equivalents and short-term investments of $19.9 million as of March 31, 2023, compared to $16.5 million as of December 31, 2022. This i...
C ash of approximately $ 19.9 million as of March 31, 202 3 , provide s ample runway to fund operations into Q2 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and GTB-5550 , and initiate cl...
News, Short Squeeze, Breakout and More Instantly...
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia Phase 1 trial with GTB-3650 anticipated to start in 2H 2024 Anticipate submitting an IND for GTB-5550 target...
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adj...
A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...